Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,050.00 Price Target at Oppenheimer

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by Oppenheimer from $950.00 to $1,050.00 in a research report report published on Monday morning, MarketBeat reports. Oppenheimer currently has a market perform rating on the biopharmaceutical company’s stock. REGN has been the subject of several other reports. Guggenheim decreased their price target on […]

Related Keywords

Bonniel Bassler ,Neil Stahl ,Cibc World Market Inc ,Markel Corp ,Sequoia Financial Advisors ,Blair William Co ,Regeneron Pharmaceuticals Stock Performance ,Securities Exchange Commission ,Regeneron Pharmaceuticals ,Wells Fargo Company ,Regeneron Pharmaceuticals Inc ,News Ratings For Regeneron Pharmaceuticals Daily ,Baird Financial Group Inc ,Regeneron Pharmaceuticals Company Profile ,Insider Transactions At Regeneron Pharmaceuticals ,Analyst Recommendations For Regeneron Pharmaceuticals ,Free Report ,Moderate Buy ,Get Free Report ,Director Bonnie ,Exchange Commission ,World Market ,Financial Advisors ,Baird Financial Group ,Financial Group ,Regeneron Pharmaceuticals Daily ,Nasdaq Regn ,Regn ,Medical ,75886f10 ,Boost Price Target ,Oppenheimer Holdings Inc ,